E.g., 09/19/2018
E.g., 09/19/2018

bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical

05 April, 2018

Marcy l’Étoile, France – April 4th, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers. In particular, Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).

bioMérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS

31 July, 2017

With more than 15,000 distinct strains, VITEK® MS provides the microbiology lab with the most comprehensive Mass Spectrometry database to improve clinical decision-making for infectious diseases 

28 July - WORLD HEPATITIS DAY 2017

28 July, 2017

Let’s eliminate hepatitis together!

bioMérieux receives FDA Clearance for BioFire’s FilmArray® Respiratory Panel 2 (RP2)

01 June, 2017

The FilmArray® RP2 reduces sample-to-result time to only 45 minutes while enhancing pathogen coverage and overall sensitivity

WORLD MENINGITIS DAY 2017

24 April, 2017

bioMérieux Spotlight: World Meningitis Day

ECCMID 2017

22 April, 2017

bioMérieux, Your Expert in Infectious Diseases at ECCMID. Together Moving Forward

Pioneering diagnostics